About Michael Lanuti, MD

After receiving a Bachelor of Science in Bioengineering from the University of Pennsylvania, Dr. Lanuti received his M.D. degree from the University of Pennsylvania School of Medicine. He completed his internship and residency in Surgery at the Hospital of the University of Pennsylvania and a two year research fellowship in a Thoracic Oncology Laboratory focusing on novel treatments for lung cancer. He continued with sub-specialty training, and completed a Cardiothoracic Fellowship at the Massachusetts General Hospital. He has been on staff in the Division of Thoracic Surgery since 2004, and holds a parallel appointment as Associate Professor of Surgery at Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004.  He is the Director of Thoracic Oncology for the Division of Thoracic Surgery and the Thoracic Surgery liaison to the MGH Cancer Center.  Clinical interests include minimally invasive surgery for lung cancer, complex airway tumors, multimodality treatment of esophageal cancer, mediastinal tumors,  navigation bronchoscopy, percutaneous and bronchoscope thermal ablation of lung tumors, and surgery for hyperhidrosis. 

Clinical Interests:




Boston: Massachusetts General Hospital

Mass General Surgery: Thoracic Surgery
55 Fruit St.
Boston, MA 02114
Phone: 617-726-2100

View location, directions and parking information for Mass General

Cooley Dickinson Hospital
30 Locust St.
Northampton, MA 01061
Phone: 413-582-2000

Medical Education

  • MD, University of Pennsylvania
  • Residency, Hospital of the Univ of Pennsylvania
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, Harvard Medical School*

American Board Certifications

  • Surgery, American Board of Surgery
  • Thoracic and Cardiac Surgery, American Board of Thoracic Surgery

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials.  The laboratory uses oncolytic viruses in combination with other modalities such as chemotherapy and angiotensin system inhibitors to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement. 

Another lab interest is molecular imaging of pulmonary fibrosis.  We have pioneered the first collagen-PET probe to be used in the quantitation of patients carrying a diagnosis of pulmonary fibrosis. This same technology is being studied in a clinical trial to better characterize radiation induced lung injury which may ultimately be used to help differentiate lung injury from tumor recurrence.  

Stage I non small cell lung cancer can still recur with a 25% chance of relapse despite complete resection.  Dr. Lanuti is investigating the role of driver mutations and gene signatures to stratify risk of recurrence in resected stage I lung adenocarcinoma. This work can contribute to adjuvant therapies for high risk resected stage I lung cancers.   

Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene which is associated with differentiation of tumor tissue.


  • Recent Publications:

    • Costantino CL, Geller AD, Wright CD, Ott HC, Muniappan A, Mathisen DJ, Lanuti M.  Carinal surgery: A single-institution experience spanning 2 decades. J Thorac Cardiovasc Surg. 2018 Dec 15.
    • Geller, AD, Zheng H, Gaissert HA, Mathisen DJ, Muniappan A, Wright CD, Lanuti M.  Relative Incremental Cost of Postoperative Complications of Esophagectomy. Sem Thor Cardiovasc Surg. 2019 Summer;31(2):290-299.
    • Geller AD, Zheng H, Mathisen DJ, Wright CD, Lanuti M. Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018 Apr;155(4):1804-1811.
    • Désogère P, Tapias LF, Hariri LP, Rotile N, Rietz TA, Probst CK, Blasi F, Day H, Elliot J, Mino-Kenudson M, Weinreb P, Violette SM, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Trans Med. 2017 Apr 5;9(384).
    • Izar B, Sequist L, Lee M, Muzikansky A, Heist RS, Iafrate AJ, Dias-Santagata D, Mathisen DJ, Lanuti M. Impact of EGFR mutation status on outcomes in patients with resected stage I NSLC. Ann Thorac Surg. 2013 Sep;96(3):962-8.
    • Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JO. Radiofrequency ablation for stage I non small cell lung cancer: management of loco-regional recurrence. Ann Thorac Surg, 2012 Mar;93(3):921-8.

Reviews: Comments and Ratings